Abstract
Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family.
Keywords: Barrett’s esophagus, Cox-2, gastrointestinal cancer, Helicobacter pylori, inflammatory bowel disease, intestinal homeostasis, tolllike receptors, tumor cell proliferation, tumor cell apoptosis.
Current Pharmaceutical Design
Title:Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer
Volume: 21 Issue: 21
Author(s): Alison C. West and Brendan J. Jenkins
Affiliation:
Keywords: Barrett’s esophagus, Cox-2, gastrointestinal cancer, Helicobacter pylori, inflammatory bowel disease, intestinal homeostasis, tolllike receptors, tumor cell proliferation, tumor cell apoptosis.
Abstract: Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family.
Export Options
About this article
Cite this article as:
West C. Alison and Jenkins J. Brendan, Inflammatory and Non-Inflammatory Roles for Toll-Like Receptors in Gastrointestinal Cancer, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514104411
DOI https://dx.doi.org/10.2174/1381612821666150514104411 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biopolymer-Based Delivery Systems: Challenges and Opportunities
Current Topics in Medicinal Chemistry Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Antiobesity Carbonic Anhydrase Inhibitors
Current Topics in Medicinal Chemistry WNT Signaling in Stem Cell Biology and Regenerative Medicine
Current Drug Targets The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Sulfur Containing Scaffolds in Drugs: Synthesis and Application in Medicinal Chemistry
Current Topics in Medicinal Chemistry Regulation of Tumor Immune Microenvironment by Sphingolipids and Lysophosphatidic Acid
Current Drug Targets The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors
Current Drug Targets Target Based Drug Design - A Reality in Virtual Sphere
Current Medicinal Chemistry Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
Current Genomics lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism First Phase Insulin Secretion and Type 2 Diabetes
Current Molecular Medicine Recent Advances and Novel Approaches for Nose to Brain Drug Delivery for Treatment of Migraine
Drug Delivery Letters The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives
Current Medicinal Chemistry